Preparing for the Next Influenza Season: Monitoring the Emergence and Spread of Antiviral Resistance
Djin-Ye Oh,Jeanette Milde,Youngsun Ham,Julia Patricia Ramos Calderón,Marianne Wedde,Ralf Dürrwald,Susanne C Duwe
DOI: https://doi.org/10.2147/IDR.S389263
2023-02-16
Infection and Drug Resistance
Abstract:Djin-Ye Oh, Jeanette Milde, Youngsun Ham, Julia Patricia Ramos Calderón, Marianne Wedde, Ralf Dürrwald, Susanne C Duwe Robert Koch Institute, Department 1: Infectious Diseases, Unit 17: Influenza and Other Respiratory Viruses, National Influenza Center, Berlin, Germany Correspondence: Susanne C Duwe, Robert Koch Institute, Department 1: Infectious Diseases, Unit 17: Influenza Viruses and Other Respiratory Viruses | National Influenza Center, Seestr. 10, Berlin, 13353, Germany, Tel +49 30 18754 2283, Fax +49 30 18754 2699, Email Purpose: The relaxation of pandemic restrictions in 2022 has led to a reemergence of respiratory virus circulation worldwide and anticipation of substantial influenza waves for the 2022/2023 Northern Hemisphere winter. Therefore, the antiviral susceptibility profiles of human influenza viruses circulating in Germany were characterized. Methods: Between October 2019 (week 40/2019) and March 2022 (week 12/2022), nasal swabs from untreated patients with acute respiratory symptoms were collected in the national German influenza surveillance system. A total of 598 influenza viruses were isolated and analyzed for susceptibility to oseltamivir, zanamivir and peramivir, using a neuraminidase (NA) inhibition assay. In addition, next-generation sequencing was applied to assess molecular markers of resistance to NA, cap-dependent endonuclease (PA) and M2 ion channel inhibitors (NAI, PAI, M2I) in 367 primary clinical samples. Furthermore, a genotyping assay based on RT-PCR and pyrosequencing to rapidly assess the molecular resistance marker PA-I38X in PA genes was designed and established. Results: While NAI resistance in the strict sense, defined by a ≥ 10-fold (influenza A) or ≥ 5-fold (influenza B) increase of NAI IC 50 , was not detected, a subtype A(H1N1)pdm09 isolate displayed 2.3- to 7.5-fold IC 50 increase for all three NAI. This isolate carried the NA-S247N substitution, which is known to enhance NAI resistance induced by NA-H275Y. All sequenced influenza A viruses carried the M2-S31N substitution, which confers resistance to M2I. Of note, one A(H3N2) virus displayed the PA-I38M substitution, which is associated with reduced susceptibility to the PAI baloxavir marboxil. Pyrosequencing analysis confirmed these findings in the original clinical specimen and in cultured virus isolate, suggesting sufficient replicative fitness of this virus mutant. Conclusion: Over the last three influenza seasons, the vast majority of influenza viruses in this national-level sentinel were susceptible to NAIs and PAIs. These findings support the use of antivirals in the upcoming influenza season. Keywords: influenza viruses, antiviral resistance, phenotypic assay, genotypic assay, surveillance, neuraminidase, cap-dependent endonuclease, baloxavir marboxil, molecular resistance marker Influenza remains one of the most important infectious diseases in the world, causing seasonal epidemics that result in estimated annual 3–5 million cases of severe illness and 300,000–500,000 deaths on a global level. 1,2 In Germany, influenza type A and B viruses usually attack 5–10% of adults and 20–30% of children, thereby causing millions of acute respiratory infections. 3 Three classes of antiviral agents have been approved for treatment and prevention of influenza infections in Germany and many other countries: M2 ion channel inhibitors (M2I), neuraminidase inhibitors (NAI) and the cap-dependent endonuclease inhibitor (PAI) baloxavir marboxil. Use of M2Is, or adamantanes, is currently not recommended due to their lack of activity against influenza B viruses, and because of the rapid emergence and transmission of drug-resistant influenza A viruses. NAIs, active against both influenza type A and type B viruses by preventing release and spread of progeny viruses, are the first-line agents recommended for influenza treatment. 3 They include oseltamivir, zanamivir and peramivir, which are administered orally, by inhalation and intravenously, respectively. Peramivir marketing authorization, granted by the European Medical Agency (EMA) in 2018, was withdrawn at the request of the license holder in December, 2020. PAIs impede the cap-dependent endonuclease activity of the influenza polymerase acidic (PA) protein. The first PAI, baloxavir marboxil, approved as an oral agent for early treatment of uncomplicated influenza in adults, received its marketing authorization in the United States and Japan in 2018 and in the EU/EEA in 2021. 3–7 The emergence and spread of viruses harboring reduced susceptibility to these antivirals may pose major challenges to the clinical management of influenza. Thus, the antiviral susceptibility assessment of currently circulating influenza viruses represent -Abstract Truncated-
pharmacology & pharmacy,infectious diseases